The Centers for Medicare and Medicaid Services (CMS) believes one PET scan is enough when doing a patient’s initial treatment evaluation, but seven medical imaging groups disagree.
PET advocates press second scan coverage
The Centers for Medicare and Medicaid Services (CMS) believes one PET scan is enough when doing a patient’s initial treatment evaluation, but seven medical imaging groups disagree. The groups this week signed a joint letter to CMS formally requesting coverage of two fluorodeoxyglucose (FDG) scans per patient under certain circumstances. They argued that limiting coverage to just one may be contrary to good clinical practice. Three examples underscoring the need for a second initial FDG/PET scan were highlighted in the letter, signed by the leadership of the National Oncologic PET Registry Working Group, the Academy of Molecular Imaging, the American College of Nuclear Medicine, the American College of Radiology, the American Society for Radiation Oncology, the Institute for Molecular Technologies and SNM. The first addresses the use of PET for the diagnosis or staging of a tumor when the course of treatment is determined to be radiation therapy and another PET scan is needed for successful radiation therapy planning. The second is when PET returns a false-negative when evaluating a suspicious lesion for a patient later diagnosed with cancer and another scan is needed for staging before treatment. The third applies to patients with newly diagnosed cancer who had to delay treatment and another scan is required to evaluate the disease after a prolonged period of time.
New MRI Research Explores Links Between Waist-to-Hip Ratio and Memory in Aging
March 13th 2025Researchers found that a higher waist-to-hip ratio in midlife was associated with higher mean diffusivity in 26 percent of total white matter tracts in the cingulum as well as the superior and inferior longitudinal fasciculus.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.